Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Wendy W, Yeh"'
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 2, Pp 401-411 (2024)
Abstract Introduction Treatment with monoclonal antibodies provides rapid, passive immunity and may stop COVID-19 disease progression. The study evaluated the effect of bamlanivimab (BAM) or BAM + etesevimab (ETE)/sotrovimab compared to placebo on SA
Externí odkaz:
https://doaj.org/article/071b45585d364709905a48a4f2a3cac4
Autor:
Jennifer E. Sager, Asma El‐Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 6, Pp 853-864 (2023)
Abstract Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non‐hospitalized high‐risk patients with mild to moderate coronavirus disease 2019 following either intraveno
Externí odkaz:
https://doaj.org/article/cbe6ae0867b34de2a58be3d836855df3
Autor:
Nancy Reau, Michael N. Robertson, Hwa‐Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach‐Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer
Publikováno v:
Hepatology Communications, Vol 1, Iss 8, Pp 757-764 (2017)
Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, l
Externí odkaz:
https://doaj.org/article/4c7209c5aab146baa45be70dea5608b3
Autor:
Jennifer E. Sager, Asma El‐Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology.
Autor:
Adrienne E. Shapiro, Elias Sarkis, Jude Acloque, Almena Free, Yaneicy Gonzalez-Rojas, Rubaba Hussain, Erick Juarez, Jaynier Moya, Naval Parikh, David Inman, Deborah Cebrik, Ahmed Nader, Nadia Noormohamed, Qianwen Wang, Andrew Skingsley, Daren Austin, Amanda Peppercorn, Maria L. Agostini, Sergio Parra, Sophia Chow, Erik Mogalian, Phillip S. Pang, David K. Hong, Jennifer E. Sager, Wendy W. Yeh, Elizabeth L. Alexander, Leah A. Gaffney, Anita Kohli
BackgroundConvenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) administra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eb08d2911a70bce8dc0f30cdc3cae2d
https://doi.org/10.1101/2023.03.21.23287410
https://doi.org/10.1101/2023.03.21.23287410
Autor:
Jennifer E. Sager, Asma El-Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes
Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death from severe disease in non-hospitalized high-risk patients with mild-to-moderate COVID-19 following either intravenous (IV) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50daa9d72af5e188fcade20242b1de3c
https://doi.org/10.1101/2022.11.23.22282478
https://doi.org/10.1101/2022.11.23.22282478
Autor:
Christine Fandozzi, Deborah Panebianco, Luzelena Caro, Dennis Wolford, Zifang Guo, Iain P. Fraser, Dennis Swearingen, Vanessa Levine, Hwa-Ping Feng, Thomayant Prueksaritanont, Joan R. Butterton, Marian Iwamoto, Wendy W. Yeh
Publikováno v:
Clinical Drug Investigation. 41:133-147
Many people infected with hepatitis C virus have comorbidities, including hypercholesterolemia, that are treated with statins. In this study, we evaluated the drug–drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and gr
Autor:
Anil, Gupta, Yaneicy, Gonzalez-Rojas, Erick, Juarez, Manuel, Crespo Casal, Jaynier, Moya, Diego, Rodrigues Falci, Elias, Sarkis, Joel, Solis, Hanzhe, Zheng, Nicola, Scott, Andrea L, Cathcart, Sergio, Parra, Jennifer E, Sager, Daren, Austin, Amanda, Peppercorn, Elizabeth, Alexander, Wendy W, Yeh, Cynthia, Brinson, Melissa, Aldinger, Adrienne E, Shapiro, Lawrence, Sher
Publikováno v:
JAMA
IMPORTANCE: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progress
Autor:
Adrienne E. Shapiro, Elias Sarkis, Jude Acloque, Almena Free, Yaneicy Gonazalez-Rojas, Rubaba Hussain, Erick Juarez, Jaynier Moya, Naval Parikh, David Inman, Deborah Cebrik, Ahmed Nadeer, Nadia Noormohamed, Qianwen Wang, Andrew Skingsley, Daren Austin, Amanda Peppercorn, Sergio Parra, Sophia Chow, Erik Mogalian, Phillip S. Pang, David K. Hong, Jennifer E. Sager, Wendy W. Yeh, Elizabeth Alexander, Leah A. Gaffney, Anita Kohli
Publikováno v:
SSRN Electronic Journal.
Autor:
Roy F. Chemaly, Wendy W. Yeh, Per Ljungman, Valerie L Teal, Randi Y. Leavitt, Cyrus Badshah, Hong Wan, Francisco M. Marty, Joan R. Butterton
Publikováno v:
American Journal of Transplantation. 20:1703-1711
Letermovir, a cytomegalovirus (CMV) terminase-complex inhibitor, is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). In a phase III, double-blind, rand